Table 2.
Analysis of T cell subsetsa in CVID patients and healthy individuals
| CVID individualsb | Healthy individualsb | P | |
|---|---|---|---|
| CD4+T (cells/μl) | 541 ± 290 | 954 ± 241 | <0·01 |
| (254–1592) | (603–1523) | ||
| CD4+HLA-DR+(%) | 17 ± 11 | 6 ± 1 | <0·01 |
| (5–42) | (4–10) | ||
| CD4+HLA-DR+(cells/μl) | 83 ± 67 | 57 ± 25 | n.s.c |
| (22–296) | (0–95) | ||
| CD4+CD45RA+CD62L+(%) | 22 ± 14 | 45 ± 9 | <0·0001 |
| (4–51) | (32–65) | ||
| CD4+CD45RA+CD62L+(cells/μl) | 127 ± 117 | 433 ± 153 | <0·0001 |
| (15–477) | (267–813) | ||
| CD4+CD45RA−CD62L+ + CD4+CD45RA+CD62L−(%) | 54 ± 9 | 41 ± 7 | <0·001 |
| (42–81) | (29–53) | ||
| CD4+CD45RA−CD62L+ + CD4+CD45RA+CD62L−(cells/μl) | 285 ± 134 | 386 ± 93 | <0·05 |
| (158–721) | (248–580) | ||
| CD8+T (cells/μl) | 633 ± 366 | 429 ± 180 | n.s.c |
| (253–1267) | (222–790) | ||
| CD8+HLA-DR+(%) | 39 ± 19 | 20 ± 10 | <0·01 |
| (11–74) | (8–39) | ||
| CD8+HLA-DR+(cells/μl) | 275 ± 250 | 87 ± 79 | <0·01 |
| (46–770) | (0–292) | ||
| CD8+CD45RA+CD62L+(%) | 38 ± 15 | 54 ± 14 | <0·01 |
| (16–66) | (28–79) | ||
| CD8+CD45RA+CD62L+(cells/μl) | 227 ± 145 | 222 ± 279 | n.s.c |
| (66–499) | (98–345) | ||
| CD8+CD45RA−CD62L+ + CD8+CD45RA+CD62L−(%) | 43 ± 10 | 30 ± 13 | <0·01 |
| (28–63) | (9–63) | ||
| CD8+CD45RA−CD62L+ + CD8+CD45RA+CD62L−(cells/μl) | 273 ± 174 | 142 ± 127 | <0·01 |
| (73–658) | (39–457) |
a
T cell subsets were investigated by flow cytometry (see Materials and methods).
b
Each value represents the mean ± s.d. and ranges are depicted in parenthesis. Statistical significance was calculated with Mann–Whitney test; P <0·05 was considered significant.
c
n.s.: not significant.